IVVD News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IV

Mkt Cap

$183.6M

Volume

2.65M

Next Earnings

November 5th

Loading chart

IV

IVVDInvivyd, Inc. Common Stock

IVVD

Pay with—

Available Balance0.00

IV

Mkt Cap

$197.1M

Volume

2.65M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease PreventionInvivyd, Inc. announced a partnership with Olympic skier Lindsey Vonn to launch a national multimedia educational campaign in spring 2026 focused on teaching Americans about antibodies and disease prevention. Vonn will serve as the public-facing spokesperson for the initiative, leveraging her credibility and comeback story to advance public understanding of antibody science and immune system health.GlobeNewswire Inc. · Jan 22, 2026

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business HighlightsInvivyd reported Q4 2025 PEMGARDA net product revenue of $17.2 million, representing 25% year-over-year growth and 31% quarter-over-quarter growth. The company announced a strong balance sheet with $226.7 million in cash after raising over $200 million in 2H 2025. Key developments include initiation of the DECLARATION Phase 3 pivotal trial for COVID vaccine-alternative VYD2311 with top-line data expected mid-2026, FDA Fast Track designation for VYD2311, and nomination of potential best-in-class RSV antibody VBY329 for preclinical development.Benzinga · Jan 8, 2026

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded WarrantsInvivyd is conducting a public offering of 44 million common stock shares and 6 million pre-funded warrants at $2.50 per share, expecting to raise approximately $125 million to fund commercial preparedness, research and development, and corporate purposes.GlobeNewswire Inc. · Nov 18, 2025

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional SharesInvivyd completed a public offering of 89,234,480 shares and pre-funded warrants, raising approximately $57.5 million to fund clinical trials, research and development, and corporate purposes.GlobeNewswire Inc. · Aug 22, 2025

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded WarrantsInvivyd is conducting a public offering of 74,811,404 common stock shares and pre-funded warrants, expecting to raise approximately $50 million to fund clinical trials, research and development, and corporate purposes.GlobeNewswire Inc. · Aug 21, 2025

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)Invivyd reported continued neutralizing activity of its COVID-19 monoclonal antibody PEMGARDA against the dominant XFG variant, with in vitro data showing consistent effectiveness and potential for ongoing protection for immunocompromised patients.GlobeNewswire Inc. · Aug 18, 2025

Invivyd Revenue Jumps 413 Percent in Q2Biotech firm Invivyd reported Q2 2025 earnings with 413% revenue growth to $11.8 million, falling short of analyst expectations. The company continues developing COVID-19 monoclonal antibodies while exploring new viral disease treatments.The Motley Fool · Aug 14, 2025

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business HighlightsInvivyd reported strong Q4 2024 revenue growth for its COVID-19 antibody PEMGARDA, and positive Phase 1 data for its next-generation candidate VYD2311. The company aims to achieve near-term profitability and continues to advance its pipeline.GlobeNewswire Inc. · Mar 20, 2025

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation ConferenceInvivyd, a biopharmaceutical company, announced its participation in the Guggenheim Securities Healthcare Innovation Conference, where it will host a fireside chat and 1x1 investor meetings.GlobeNewswire Inc. · Nov 6, 2024

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024Invivyd, a biopharmaceutical company, announced that it will host a conference call on November 14, 2024, to discuss its financial results for the third quarter of 2024 and provide recent business highlights.GlobeNewswire Inc. · Nov 6, 2024

to start trading

IV

IVVDInvivyd, Inc. Common Stock

IVVD

Pay with—

Available Balance0.00

Your PositionYou don't own any IVVD yet.

Related Tickers

Earnings